Epidemiological aspects of Budd-Chiari in Egyptian patients: A single-center study

Table 3 Relationship between gender and etiology in patients with Budd-Chiari syndrome (n = 94)

Etiology		Gender n (%)		χ²	P value	Sig
		Male	Female
PC deficiency	+	1 (2.90)	3 (5.20)		1	NS
PS deficiency	+	1 (2.90)	0 (0.00)		0.38	NS
AT III deficiency	+	2 (5.70)	2 (3.40)		0.63	NS
FVLM	Homozygous	5 (20.80)	5 (12.50)	1.77	0.18	NS
	Heterozygous	6 (25.00)	18 (45.00)
PGM	Homozygous	0 (0.00)	1 (2.60)	1.54	0.21	NS
	Heterozygous	0 (0.00)	2 (5.10)
MTHFR	Homozygous	6 (28.60)	2 (5.10)	8.41	0.01	HS
	Heterozygous	9 (42.90)	14 (35.90)
JAK2 (MPD)	+	6 (28.60)	12 (29.30)	0.003	0.95	NS
Primary APA	+	5 (13.90)	11 (19.00)	0.4	0.52	NS
Secondary APA	+	1 (2.80)	10 (17.20)		0.05 S
Behçet’s disease	+	11 (30.60)	1 (1.70)	< 0.001 VHS
PNH	+	1 (2.80)	1 (1.70)		1 NS

Sig: Significance; NS: Not significant; S: Significant; HS: Highly significant; VHS: Very highly significant; PC: Protein C; PS: Protein S; AT: Antithrombin; FVLM: Factor V Leiden mutation; PGM: Prothrombin gene mutation; MTHFR: Methylene tetrahydrofolate reductase; JAK2: Janus tyrosine kinase-2; MPD: Myeloproliferative disorder; APA: Antiphospholipid antibody syndrome; PNH: Paroxysmal nocturnal hemoglobinuria.